Immune Checkpoint Inhibition in Locally Advanced, Recurrent, and Metastatic Cutaneous Squamous Cell Carcinoma
Immune-boosting drugs show encouraging early results for advanced skin cancer when used before or after surgery, potentially improving disease-free survival.
Cutaneous squamous cell carcinoma (cSCC) is a potentially aggressive non-melanoma skin cancer with rising incidence attributed to ultraviolet radiation exposure, chronic inflammation, aging, immunosuppression, and improved detection technology. The reported conclusion is: Active investigations into the efficacy of ICIs in advanced resectable and unresectable cSCC are rapidly shifting management with evidence revealing promises of greater disease-free survival through neoadjuvant and adjuvant approaches.
What the study was
- Study design
- Randomized controlled trial
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinics in dermatology
Why it surfaced
Retained for Novel therapeutics; score reflects the available PubMed abstract, study design, clinical relevance, and unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.